RAND, United States.
RAND, United States.
J Health Econ. 2024 Sep;97:102917. doi: 10.1016/j.jhealeco.2024.102917. Epub 2024 Jul 17.
Despite efforts to expand naloxone access, opioid-related overdoses remain a significant contributor to mortality. We study state efforts to expand naloxone distribution through pharmacies by reducing the non-monetary costs to prescribers, dispensers, and/or potential recipients of naloxone. We find that laws that only address liability costs have small and insignificant effects on the volume of naloxone dispensed through pharmacies. In contrast, we estimate large effects of laws removing the need for patients to obtain prescriptions from traditional prescribers (e.g., primary care physicians): laws authorizing non-patient-specific prescription distribution and laws granting pharmacists prescriptive authority. We test whether areas designated as primary care shortage areas-where it would be costlier to obtain a prescription-were disproportionately impacted. Shortage areas experienced sharper growth in pharmacy naloxone dispensing in states adopting prescriptive authority policies. These gains were primarily due to those facing low out-of-pocket costs, suggesting that price barriers also must be addressed to increase naloxone purchases.
尽管已经努力扩大纳洛酮的获取途径,但阿片类药物相关的过量用药仍是导致死亡的主要原因之一。我们研究了各州通过降低处方医生、药剂师和/或潜在纳洛酮接受者的非货币成本,来扩大通过药店分发纳洛酮的努力。我们发现,仅解决责任成本的法律对通过药店分发的纳洛酮数量的影响很小且不显著。相比之下,我们估计消除患者从传统处方医生(例如初级保健医生)获得处方的必要性的法律具有很大的影响:授权非患者特定处方分发的法律和赋予药剂师处方权的法律。我们测试了是否将指定为初级保健短缺地区(在这些地区获得处方的成本更高)受到不成比例的影响。在采用处方授权政策的州,短缺地区的药店纳洛酮配药量增长更为明显。这些收益主要归因于那些面临较低自付费用的地区,这表明还必须解决价格障碍以增加纳洛酮的购买量。